Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $70.00 at HC Wainwright

Pacira BioSciences (NASDAQ:PCRX) had its price target lifted by HC Wainwright from $57.00 to $70.00 in a research note released on Friday,Benzinga reports. They currently have a buy rating on the stock.

PCRX has been the subject of several other reports. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their price objective for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Barclays dropped their price objective on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 12th. Finally, Needham & Company LLC lifted their price objective on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Pacira BioSciences currently has a consensus rating of “Hold” and an average price target of $27.22.

Pacira BioSciences Trading Down 5.2 %

Shares of PCRX opened at $24.05 on Friday. The company’s fifty day moving average is $23.16 and its 200 day moving average is $18.58. Pacira BioSciences has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The stock has a market capitalization of $1.11 billion, a PE ratio of -11.85 and a beta of 0.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

Institutional Trading of Pacira BioSciences

Hedge funds have recently added to or reduced their stakes in the business. Sterling Capital Management LLC lifted its stake in Pacira BioSciences by 779.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after acquiring an additional 1,208 shares during the period. Ancora Advisors LLC purchased a new stake in Pacira BioSciences in the fourth quarter worth about $26,000. Caitlin John LLC lifted its stake in Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after acquiring an additional 1,776 shares during the period. Nisa Investment Advisors LLC lifted its stake in Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after acquiring an additional 2,749 shares during the period. Finally, PNC Financial Services Group Inc. lifted its stake in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after acquiring an additional 513 shares during the period. 99.73% of the stock is owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.